Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Shanghai Menon Animal Nutrition Technology
301156
5
Nanjing Railway New Technology
301016
US Stock MarketDetailed Quotes
CNTX Context Therapeutics
- 0.5991
- -0.1199-16.68%
Close Apr 4 16:00 ET
- 0.5991
- 0.00000.00%
Post 16:20 ET
53.74MMarket Cap-1.30P/E (TTM)
0.7200High0.5851Low478.13KVolume0.7000Open0.7190Pre Close299.33KTurnover1.18%Turnover RatioLossP/E (Static)89.70MShares2.750052wk High0.56P/B24.30MFloat Cap0.550052wk Low--Dividend TTM40.56MShs Float10.8700Historical High--Div YieldTTM18.76%Amplitude0.4700Historical Low0.6260Avg Price1Lot Size
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Context Therapeutics Stock Forum
Context Therapeutics Secures 3-Year Cash Runway with $94M War Chest, Expands Cancer Pipeline
“Life-Saving Opoid Overdose Nasal Spray”
4.72 mil free float
ﾟ* ҉* ੈ‧₊ ｡ﾟnot financial advice ⋆⋆♡
PR Newswire· 5 mins ago
PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6) bispecific antibody, CTIM-76, has been dosed in the first patient in a Phase 1 clinical trial by its licensing partner, Context Therapeutics Inc. Th...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
📊⚡️📊
CTIM-76's development targets a significant unmet need in CLDN6-positive cancers. The bispecific antibody's mechanism of action, engaging T cells to target CLDN6-expressing tumor cells, represents a sophisticated approach in immuno-oncology. Recent SITC presentation data supporting the first-in-human dose selection indicates robust preclinical validation.
For investors, thi...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Tuesday, 14th January at 4:58 pm
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers
Trial marks key milestone in driving pipeline progress
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today anno...
No comment yet